Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miebo in dry eye disease
NCT06309953Phase 4Completed
- Sponsor
- Bausch + Lomb
- Start
- Feb 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of perfluorohexyloctane in dry eye disease (DED), sponsored by Bausch + Lomb. Primary endpoint: Mean Change From Baseline in Dry Eye Symptom Severity at 7 days. Started Feb 2024; status: completed.
02
Drugs
perfluorohexyloctane
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06309953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06309953.